8 recruiting, 7 completed, 4 active not recruiting, 3 terminated. 26 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 26 | Recruiting 8, Completed 7, Active not recruiting 4, Terminated 3, Withdrawn 2, Not yet recruiting 1, Suspended 1 |
Follow Primary Dysautonomias: new trials by email Literature Review of Primary Dysautonomias trials Research Report on Primary Dysautonomias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial Guanfacine (GFC), Cromolyn Sodium, Placebo - Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia | Early Phase 1 | Not yet recruiting | Johns Hopkins University | 25 | 2026-11-15 | 2026-10-09 |
| Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase [11C]MODAG-005 - Parkinson Disease (PD), MSA - Multiple System Atrophy | Early Phase 1 | Recruiting | MODAG GmbH | 9 | 2026-07-29 | 2026-07-31 |
| Expansion Study of ALT001 in Patients With Multiple System Atrophy ALT001 - Multiple System Atrophy | Early Phase 1 | Recruiting | yilong Wang | 60 | 2026-06-15 | 2026-09-09 |
| The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type ALT001 - Multiple System Atrophy - Cerebellar Subtype (MSA-C) | Early Phase 1 | Recruiting | yilong Wang | 20 | 2026-06-10 | 2026-09-09 |
| Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers [¹⁸F]MODAG-009 PET Imaging - Healthy Adult | Early Phase 1 | Recruiting | MODAG GmbH | 6 | 2026-05-27 | 2026-06-04 |
| Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies [¹⁸F]MODAG-009 PET imaging - Multiple System Atrophy (MSA), Healthy Adult | Early Phase 1 | Recruiting | MODAG GmbH | 13 | 2026-05-13 | 2026-06-10 |
| The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy Aleeto - Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, MSA | Early Phase 1 | Recruiting | Beijing Tiantan Hospital | 20 | 2025-05-31 | 2025-09-03 |
| [18F]ACI-15916 PET in α-synucleinopathies [18F]ACI-15916 - Parkinson's Disease (PD), Multiple System Atrophy (MSA) | Early Phase 1 | Recruiting | AC Immune SA | 46 | 2025-03-20 | 2026-10-28 |
| PET Imaging Evaluation of [11C]SY08 C11-SY08 - Parkinson's Disease, Multiple System Atrophy | Early Phase 1 | Recruiting | Massachusetts General Hospital | 40 | 2024-05-01 | 2025-12-24 |
| Role of Endothelin-1 Modulating Insulin-stimulated Blood Flow and Sympathetic Nervous System Activity in Obesity Hyperinsulinemic, euglycemic infusion - Insulin Resistance, Autonomic Dysfunction | Early Phase 1 | Withdrawn | University of Missouri-Columbia | 2024-02-01 | 2024-02-20 | |
| Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation Carbon dioxide breathing, Neurovascular Coupling, Human insulin - Healthy, Vasodilation | Early Phase 1 | Suspended | University of Missouri-Columbia | 65 | 2021-12-01 | 2025-12-19 |
| Autonomic Determinants of POTS - Pilot 2 Placebo oral tablet, Moxonidine Pill - Postural Tachycardia Syndrome | Early Phase 1 | Active not recruiting | Vanderbilt University Medical Center | 48 | 2021-08-31 | 2026-03-27 |
| Histamine as a Molecular Transducer of Adaptation to Exercise Aerobic Exercise, alpha-FMH, Resistance and Aerobic Exercise - Postexercise Hypotension | Early Phase 1 | Active not recruiting | University of Oregon | 80 | 2021-07-28 | 2026-01-23 |
| The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease Yohimbine HCl - Parkinson Disease | Early Phase 1 | Withdrawn | Nathaniel M. Robbins | 2021-05-11 | 2023-08-23 | |
| Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients [F-18]PBR06, Verdiperstat - Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant | Early Phase 1 | Completed | Brigham and Women's Hospital | 19 | 2020-12-30 | 2022-08-19 |
| Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain [18F]MNI-1216 - Alpha-Synucleinopathy, Parkinson's Disease | Early Phase 1 | Completed | Invicro | 12 | 2020-12-24 | 2025-02-19 |
| Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients Midodrine, Placebo pill, Abdominal compression - Neurogenic Orthostatic Hypotension, Autonomic Failure | Early Phase 1 | Completed | Vanderbilt University Medical Center | 31 | 2020-11-09 | 2026-08-07 |
| Autonomic Determinants of POTS - Pilot1 Moxonidine, Placebo - Postural Tachycardia Syndrome | Early Phase 1 | Active not recruiting | Vanderbilt University Medical Center | 48 | 2019-08-27 | 2026-03-27 |
| Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension Yohimbine, Melatonin - Hypotension, Orthostatic, Hypertension | Early Phase 1 | Terminated | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 10 | 2018-03-01 | 2019-06-12 |
| Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS Pyridostigmine, Digoxin, Placebo - Postural Orthostatic Tachycardia Syndrome (POTS), POTS | Early Phase 1 | Completed | New York Medical College | 51 | 2017-07-01 | 2022-09-28 |
Showing 20 of 26. Sign in to see all of them.
Multiple System Atrophy (11) · Parkinson Disease (8) · Postural Orthostatic Tachycardia Syndrome (7) · Orthostatic Intolerance (5) · Autonomic Nervous System Diseases (4) · Lewy Body Disease (3) · Pure Autonomic Failure (3) · Shy-Drager Syndrome (3) · Hypertension (2) · Hypotension, Orthostatic (2) · Insulin Resistance (2) · Obesity (2) · Syncope, Vasovagal (2) · Aneurysm (1)
Nervous System Diseases (25) · Autonomic Nervous System Diseases (22) · Basal Ganglia Diseases (14) · Brain Diseases (14) · Central Nervous System Diseases (14) · Movement Disorders (14) · Neurodegenerative Diseases (13) · Synucleinopathies (12) · Pathological Conditions, Signs and Symptoms (9) · Parkinsonian Disorders (8) · Signs and Symptoms (8) · Cardiovascular Diseases (7) · Vascular Diseases (7) · Hypotension (6)
Saline Solution (2) · Yohimbine (2) · moxonidine (2) · Acetates (1) · Ascorbic Acid (1) · Cromolyn Sodium (1) · Digoxin (1) · Drinking Water (1) · Exercise (1) · Guanfacine (1) · Heating (1) · Histamine Antagonists (1) · Insulin (1) · Losartan (1) · Melatonin (1)
Vanderbilt University Medical Center (5) · MODAG GmbH (3) · New York Medical College (3) · University of Missouri-Columbia (2) · yilong Wang (2) · AC Immune SA (1) · Beijing Tiantan Hospital (1) · Brigham and Women's Hospital (1) · Dhanunjaya Lakkireddy, MD, FACC (1) · Invicro (1) · Johns Hopkins University (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Massachusetts General Hospital (1) · Nathaniel M. Robbins (1) · University of Oregon (1)
United States (19) · China (3) · Canada (1) · Germany (1) · Sweden (1)
Jacqueline K Limberg, Ph.D. (2) · Julian M. Stewart, M.D., Ph.D. (2) · Tao Feng (2) · Yilong Wang (2) · Andrea Varrone, Prof. (1) · David Russell, MD (1) · Dhanunjaya Lakkireddy, MD, FACC (1) · Emily M Garland, PhD, MSCI (1) · Italo Biaggioni, M.D. (1) · Italo Biaggioni, MD (1) · John R Halliwill, PhD (1) · Julian M Stewart, MD, PhD (1) · Luis Okamoto, MD (1)
2023 (1), 5UL1TR000445-07 (1), P01HL056693 (1), R01HL142583 (1), R01HL144568 (1), R56HL142583 (1), UL1TR000445 (1)